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Analyses of cancer incidence data in the United States
and Western Europe revealed steadily rising rates
over the past decades of adenocarcinomas of the
esophagus and gastric cardia. Genetic information on
gastric cardia adenocarcinoma and its preneoplasias
is sparse. We have used comparative genomic hybrid-
ization to obtain a genome-wide overview of 20 archi-
val gastric cardia adenocarcinomas and 10 adjacent
preneoplastic lesions (4 metaplasias, 1 low-grade dys-
plasia , 5 high-grade dysplasias). Multiple genetic al-
terations were discriminated in all adenocarcinomas.
Frequent loss (>25% of all tumors) was detected, in
decreasing order of frequency, on 5q, 18q, 4q, 3p,
9p, 2q, 11q, 14q, 21q, 4p, 9q, 16q, 1p, and 8p. Fre-
quent gain (>25% of all tumors) was disclosed, in
decreasing order of frequency, on 20q, 7p, 8q, 1q,
7q, 20p, 17q, 13q, Xp, 6q, 8p, 19q, 5p, 6p, and Xq.
Loss of the Y chromosome was found in 60% of male
cases. High level amplification was frequently (>10%
of all tumors) detected on 7q21, 8p22, 12p11.2,
17q12-q21, and 19q13.1-q13.2. The precursor lesions
showed multiple aberrations in all high-grade dyspla-
sias, whereas few genetic changes were discerned in
LGD and metaplasias. High level amplifications were
also found in high-grade dysplasias, ie, on 7q21, 8p22,
and 17q12-q21. Moreover, the percentage of aberra-
tions was not significantly different for invasive carci-
nomas or high-grade dysplasias. Approximately 70% of
the precursor aberrations were also present in the ad-
jacent carcinoma. Minimal overlapping regions in the
preneoplasias included loss on 18q12-q21 and gains on
8q23 and 17q12-q21, suggesting involvement of genes
residing in these regions. In conclusion, we have (i)
created a map of genetic alterations in gastric cardia
adenocarcinomas and (ii) provided evidence for the
presence of a metaplasia-dysplasia-carcinoma sequence
in this poorly understood type of cancer. (Am J Pathol
2001, 158:1961–1967)
The incidence of adenocarcinomas arising around the
gastro-esophageal junction has shown steadily rising
rates over the past decades in the Western world.1,2 A
five- to sixfold increase was reported between 1970 and
1990.3,4 Overall, cancer of the esophagus is increasing,
and stomach cancer is decreasing. However, when an-
alyzed by histological type and subsite, the picture is
very different. In esophagus, squamous cell carcinoma
rates have remained stable, whereas a rapid increase of
adenocarcinoma is observed. In stomach, cardia cancer
shows a very similar pattern to adenocarcinoma of the
esophagus, but pyloric-antrum cancer is decreasing. Ad-
enocarcinomas of the gastro-esophageal junction region
disproportionately affect white men and occur less fre-
quently among women.1,5 The simultaneously increased
incidence at the different locations suggest that adeno-
carcinomas of the gastro-esophageal junction are re-
lated. Reflux disease has been suggested as an etiolog-
ical factor not only in esophageal adenocarcinoma, but
also in cancer of the gastric cardia.6 Esophageal and
gastric cardia adenocarcinomas have in common that
they arise around the gastro-esophageal junction. Esoph-
ageal adenocarcinoma is strongly correlated with Bar-
rett’s esophagus. In Barrett’s esophagus, the squamous
cell epithelium has undergone metaplastic change to
columnar epithelium as a result of long-standing gastro-
esophageal reflux.7,8 Metaplastic change has also been
observed at the gastro-esophageal junction, which also
might explain the rising frequency at this location.9 Intes-
tinal metaplasia of the gastric cardia has been reported;
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however, its relation with malignant transformation is
presently not clear.10,11 Adenocarcinomas of the esoph-
agus and gastric cardia share a poor prognosis, due to
aggressive tumor behavior, as well as late detection.12,13
Cytogenetic studies of series of both gastric and
esophageal adenocarcinomas have shown frequent
chromosomal rearrangement of 11p13–1514 and deletion
of 3q.15 In a study of 37 adenocarcinomas in Barrett’s
esophagus and gastric cardia, loss of the Y chromosome
appeared to be a prominent feature.16 Further, rear-
rangements were most frequently seen of chromosome
arms 1p, 3q, 11p, and 22q. Genetic abnormalities have
been extensively documented in the formerly common
pyloric-antrum type of gastric cancer. Patterns of gene
amplification have been investigated.17 Ranzani et al18
detected loss of heterozygosity (LOH) at 5q, 11p, 17p,
and 18q, and with a low frequency also at 7q and 13q. In
these gastric cancers deletions often occur at the APC
and MCC loci on 5q21.19 Little is known of LOH in gastric
cardia tumors. In a study of adenocarcinoma of the gas-
tric cardia frequent allelic loss was seen on 3p, 4q, 5q,
8p, 9pq, 12q, 13q, 17p, and 18q.20 A comparison of
esophageal and gastric cardia cancers revealed similar
patterns of TP53 alterations.21 Comparative genomic hy-
bridization of gastro-esophageal junction cancers was
reported including limited numbers of gastric cardia car-
cinomas.22–24 Gain of chromosome 20 was most fre-
quently found. Further, prominent gain was seen on 1q,
7pq, 8q, 13q, 15q, and 17q, and loss was observed on
4pq, 5q, 9p, 14q, and 18q. Recurrent high-level amplifi-
cations were disclosed at 8q23–24.1, 17q12–21, and
19q13.1.
In this study we wanted to document the spectrum of
genetic changes in a series of gastric cardia adenocar-
cinomas and surrounding preneoplastic lesions. We were
especially interested in a metaplasia-dysplasia-carci-
noma sequence in this type of cancer. Therefore, we
collected metaplastic and dysplastic tissues from archi-
val resection specimens of gastric cardia adenocarcino-
mas. To our knowledge such an investigation has not
been reported. Comparative genomic hybridization
(CGH) was used to obtain a genome-wide view of chro-
mosomal gains and losses.
Materials and Methods
Patient Material
We collected 20 surgical specimens with adenocarcino-
mas of the gastric cardia, ie, the center of the tumor was
clearly located in the proximal stomach. Barrett’s epithe-
lium was absent in all cases. The presence of Helicobac-
ter pylori infection was evaluated on routine H&E sections,
but in difficult cases special stains were used. Special
attention was given to the selection of preneoplastic le-
sions (metaplasia, dysplasia) in the vicinity of the tumor.
Intestinal metaplasia was defined as the presence of
goblet cells in gastric epithelium. Precursors were se-
lected from 10 resection specimens. In the other 10
cases no preneoplasias could be found, possibly due to
overgrowth of these generally large cancers. Fourteen of
the tumor specimens were derived from paraffin-embed-
ded, formalin-fixed, materials; six were fresh-frozen. All
preneoplastic lesions were paraffin-embedded. Staging
of the tumors was performed according to the Union
Internationale Contre le Cancer (UICC).25
Comparative Genomic Hybridization
Isolation of DNA from the formalin-fixed, paraffin-embed-
ded tumor material was performed using standard pro-
cedures. Microdissection of the tumor areas was per-
formed using a hollow bore coupled to the microscope.
Metaplastic and dysplastic areas were scraped from
10-mm paraffin sections using a stereo microscope and a
0.4 3 12 mm hollow needle. DNA from both fresh-frozen
and archival paraffin samples was isolated according to
standard protocols, and concentration, purity, and mo-
lecular weight of the DNA were estimated. Tumor DNA
with a fragment size of ,1 kb was labeled with a plati-
num/biotin complex (bio-ULS), using the ULS biotin la-
beling kit (Kreatech Diagnostics, Amsterdam, The Neth-
erlands.)26 Tumor DNA with larger DNA fragment sizes
was labeled with biotin by nick translation (Nick Transla-
tion System, Gibco BRL, Gaithersburg, MD). Likewise,
male reference DNA (Promega, Madison, WI) was la-
beled by nick translation with digoxigenin (Boehringer
Mannheim, Indianapolis, IN). The reaction time and the
amount of DNase were adjusted to obtain a matching
probe size for reference and tumor DNAs. Molecular
weight of both tumor and reference DNA was checked by
gel electrophoresis after nick translation, and ranged
between 500 and 1500.
CGH was performed as described before.24,26 In brief,
400 ng of labeled archival tumor DNA, 200 ng of refer-
ence DNA, and 15 mg of unlabeled Cot-1 DNA were
ethanol-precipitated and dissolved in 10 ml of hybridiza-
tion mixture (50% formamide, 0.1% Tween-20, and 10%
dextran sulfate in 23 standard saline citrate at pH 7.0).
The probe mixture was denatured and hybridized to nor-
mal male metaphase chromosomes (Vysis, Downers
Grove, IL) for 3 days at 37°C. After washing of the slides,
fluorescent detection of the biotin- and digoxigenin-la-
beled DNA probes was accomplished with avidin-fluo-
rescein isothiocyanate and anti-digoxigenin rhodamine,
respectively. Samples were counterstained with 49,69-
diamidino-2-phenyl indole (DAPI) in anti-fade solution.
Images were acquired with an epifluorescent micro-
scope (Leica DM, Rijswijk, The Netherlands) equipped
with a CCD camera (Photometrics, Tucson, AZ), three
single excitation filters, a multiband pass dichroic mirror,
and emission filters. For comparative genomic hybridiza-
tion analysis Quips XL software (version 3.1.1; Vysis) was
used. Loss of DNA sequences was defined as chromo-
somal regions where the mean green to red ratio was
,0.85, whereas gain was defined as chromosomal re-
gions where the ratio was .1.15. These threshold values
were based on series of normal controls. A high-level
amplification, probably representing an amplicon, was
seen as a distinct peak (ratio .1.5). At least 8 to 10
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metaphases per sample were used for the analysis of
gains and losses.
Results
Gastric Cardia Adenocarcinomas
We have used CGH to obtain a genome-wide overview of
20 archival gastric cardia adenocarcinomas (17 males, 3
females) and 10 adjacent preneoplastic lesions: 4 meta-
plasias, 1 low-grade dysplasia (LGD), and 5 high-grade
dysplasias (HGD; see Table 1). Intestinal metaplasia was
found in the vicinity of 6 tumors (30%), whereas H. pylori-
associated gastritis was present in 3 cases (15%). Mul-
tiple genetic alterations were discriminated in all adeno-
carcinomas (Figure 1A). Frequent loss ($25% of all
tumors) was detected, in decreasing order of frequency,
on 5q (55%), 18q (55%), 4q (50%), 3p (45%), 9p (45%),
2q (40%), 11q (35%), 14q (35%), 21q (35%), 4p (30%),
9q (30%), 16q (30%), 1p (25%), and 8p (25%). Frequent
gain ($25% of all tumors) was disclosed, in decreasing
order of frequency, on 20q (80%), 7p (70%), 8q (60%),
1q (55%), 7q (55%), 20p (45%), 17q (40%), 13q (35%),
Xp (35%), 6q (30%), 8p (30%), 19q (30%), 5p (25%), 6p
(25%), and Xq (25%). Loss of the Y chromosome was
found in 60% of male cases. Minimal overlapping regions
for loss were assigned to 3p14, 5q21, 5q31-q33, 8p21-
p22, 9p21, 11q24-q25, 14q23-q24, 18q12-q21, and
21q21, whereas minimal overlapping regions for gain
were assigned to 1q41-q42, 7p12-p14, 7q21, 8p22,
8q21.3-q23, 12p11.2, 13q12-q14, 17q12-q21, 19q13.1-
q13.2, and 20q11.2-q13.1. Recurrent (.10% of all tu-
mors) high-level amplification (HLA) was detected on
7q21, 8p22, 12p11.2, 17q12-q21, and 19q13.1-q13.2,
illustrating the genomic instability in these carcinomas.
Metaplasia-Dysplasia-Carcinoma Data
The precursor lesions showed multiple aberrations in all
HGDs, whereas few genetic (mostly non-frequent)
changes were discerned in LGD and metaplasias (Figure
1B). Frequent gains included 8q (40%), 6p (30%), 7q
(30%), 13q (30%), 17q (30%), and 20q (30%), whereas
frequent losses were seen on 18q (50%), Y (40%), 2q
(30%), 4p (30%), 5q (30%), 9p (30%), and 21q (30%).
HLAs were found only in HGD: two on 17q12-q21, one on
7q21, and one on 8p22. The mean percentage of aber-
rations in the 20 adenocarcinomas appeared only slightly
higher than in the 6 dysplasias (11.9 vs. 10.6, respective-
ly). This was caused by the 5 HGDs in this set of dyspla-
sias (Table 2). The 4 metaplasias showed an average of
0.7 alterations per lesion. Approximately 70% of the pre-
Table 1. Patient and Tumor Data
Sex/age Grade* Stage† Precursor HP-gastritis
1 M/75 G2 T1N0M0 HGD 2
2 M/75 G3 T2N2M0 LGD 2
3 M/63 G3 T2N0M0 MET 1
4 M/50 G1 T1N0M0 HGD 2
5 F/75 G2 T2N2M0 HGD 2
6 M/71 G3 T2N1M0 HGD 2
7 M/67 G2 T2N0M0 HGD 2
8 F/71 G3 T3N1M0 MET 1
9 M/54 G3 T3N1M0 MET 2
10 M/32 G2 T3N2M0 MET 2
11 M/63 G1 T2N1M0 n.a. 2
12 M/57 G2 T2N1M0 n.a. 2
13 M/54 G3 T3N1M0 n.a. 2
14 M/75 G2 T3N1M0 n.a. 2
15 M/58 G3 T3N2M0 n.a. 2
16 M/69 G2 T2N0M0 n.a. 2
17 M/45 G3 T2N0M0 n.a. 2
18 M/56 G1 T3N1M0 n.a. 2
19 M/70 G3 T3N1M0 n.a. 2
20 F/72 G3 T3N1M0 n.a. 1
*G1, well differentiated; G2, moderately differentiated; G3, poorly
differentiated.
†Tumor-node-metastasis classification according to the UICC,25 in
brief: T1, tumor invades mucosa or submucosa; T2, muscularis propria
or gastric subserosa; T3, gastric serosa or adjacent esophageal
adventitia. N0, no lymph node metastasis; N1, 1–6 positive nodes; N2,
7–15 positive nodes. M0, no distant metastases.
MET, metaplasia; LGD, low-grade dysplasia; HGD, high-grade
dysplasia; n.a., not available (possibly due to overgrowth of the
generally large cancer); HP-gastritis, Helicobacter pylori-associated
gastritis.
Figure 1. A: Chromosomal ideograms showing the summary of DNA copy
number changes, detected by CGH in 20 gastric cardia adenocarcinomas.
Losses are displayed (as bars) on the left of the ideogram, gains are shown
on the right. Frequent loss is seen on 1p, 2q, 3p, 4pq, 5q, 8p, 9pq, 11q, 14q,
16q, 18q, 21q, and Y. Frequent gain is detected at 1q, 5p, 6pq, 7pq, 8pq, 13q,
17q, 19q, 20pq, and Xpq. High level amplification (HLA; marked by an open
bar) was frequently detected on 7q21, 8p22, 12p11.2, 17q12-q21, and
19q13.1-q13.2. B: Chromosomal ideograms showing the summary of DNA
copy number changes, detected by CGH in 10 preneoplastic lesions (4
metaplasias, 1 low-grade dysplasia, 5 high-grade dysplasias). Frequent loss
can be discriminated on 2q, 4p, 5q, 9p, 18q, 21q, and Y; frequent gain is seen
on 6p, 7q, 8q, 13q, 17q, and 20q. HLAs were found only in high-grade
dysplasia on 7q21, 8p22, and 17q12-q21.
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cursor aberrations were also present in the adjacent car-
cinoma, illustrating the presence of a metaplasia-dyspla-
sia-adenocarcinoma sequence in gastric cardia cancer
(Table 2 and Figure 2). A high percentage of concurrent
alterations were seen in HGD and invasive cancer, de-
spite the evident differences in histomorphology (Figure
2, C–F). Overlapping alterations were not only seen in
HGD, but also in LGD (case 2), and even in intestinal
metaplasia (cases 3 and 10). Minimal overlapping re-
gions in the preneoplasias included loss on 18q12-q21
and gains on 8q23 and 17q12-q21, suggesting involve-
ment of genes in these regions in the development of
cancer of the proximal stomach.
Discussion
In this study we have created a genome-wide map of
genetic alterations in gastric cardia adenocarcinomas.
Furthermore, we have provided evidence of the presence
of a metaplasia-dysplasia-carcinoma sequence in this
type of cancer. Intestinal metaplasia of the gastro-esoph-
ageal junction is found in approximately 10 to 40% of
patients without long segments of Barrett’s mucosa.
Spechler et al9 reported that 15 to 20% of adults under-
going elective upper endoscopy had segments of intes-
tinal metaplasia at the gastro-esophageal junction that
were not recognized by endoscopy. Trudgill et al27 also
concluded that intestinal metaplasia at the junction is a
common finding. In our study a high percentage of over-
lapping alterations was found between adenocarcinomas
and preneoplasias. Interestingly, in two of the metapla-
sias aberrations were already discerned: In case 10 a
non-frequent alteration that was also seen in the adeno-
carcinoma, in case 3 two changes, one of which was
present in the cancer. Comparable numbers of chromo-
somal aberrations, as well as a very high percentage of
overlap, were found in HGDs and invasive carcinomas
despite clearly non-invasive versus invasive growth pat-
terns. Thus, a discrepancy seems present between phe-
notypic and genotypic characteristics in HGD, leading
us to speculate that the apparently non-invasive histo-
morphology of HGD might actually represent well-differ-
entiated adenocarcinoma.
We have disclosed frequent alterations in gastric car-
dia cancers and precursors, and minimal overlapping
regions could be assigned at multiple locations. Below
we will discuss the most prevalent and relevant candi-
date genes for these frequent chromosomal regions of
gain or loss in the adenocarcinomas28,29 (also listed on
the genecards database of the Weizmann Institute at
http://bioinfo.weizmann.ac.il/cards).
Chromosomal Loss
In the literature only one detailed study has been re-
ported describing LOH solely in gastric cardia adenocar-
cinomas.20 Recurrent allelic losses (.50%) were seen on
3p, 4q, 5q, 8p, 9p, 9q, 12q, 13q, 17p, and 18q. In our
series the most frequent losses were noted on chromo-
some arms 5q and 18q (both 55% of cases), whereas
less frequent deletions were found on 1p, 2q, 3p, 4p, 4q,
8p, 9p, 9q, 11q, 14q, 16q, and 21q. Thus, a good con-
cordance is present between these two studies using
different methodologies. A discrepancy between the two
series is our low percentage of deletions on distal 17p
within the TP53 (tumor protein p53) region. It might be
Table 2. Genetic Aberrations in Preneoplastic Lesions of the Gastric Cardia
Patient Precursor Aberrations
1 HGD loss: 2q21-q22, 4p14-pter, 5p13-pter, 5q12-q33, 9p13-pter, 11q21-qter, 12q21
gain: 6p11.2-p21.3, 7q32-q34, 8q23, 19p13.1-pter, 19q13.1-q13.2
2 LGD loss: n.a.
gain: 17q21-qter
3 MET loss: 18q12-q21
gain: X
4 HGD loss: 1p21-p31, 1q23-qter, 2p12-pter, 2q13-q31, 3p13-pter, 4, 9p13-pter, 18, Y
gain: 6p11.2-p22, 6q12-q15, 7q11.2-q22, 13q12-q22, 17q11.2-q21 (HLA 17q12-q21),
Xq12-qter
5 HGD loss: 12, 18q12-qter, 19, 21q11.2-qter, 22
gain: 8q22-qter, 13, 20
6 HGD loss: 2p23-pter, 5q12-qter, 9p13-pter, 9q21-q32, 15q11.2-q24, 17p12, 18q11.2-qter,
21, 22, Y
gain: 1q32-qter, 5p14-pter, 7p11.2-pter, 7q11.2-q22 (HLA 7q21), 8 (HLA 8p22-q23),
12p11.2-p12, 20
7 HGD loss: 1p13-pter, 1q41-q42, 2q31-qter, 3, 4, 5q12-qter, 8p21-pter, 10q22-qter, 14q13-
qter, 16q13-qter, 18q12-qter, 20p11.2-p12, 21, Y
gain: 5p12-pter, 6p11.2-p23, 6q12-q24, 7p11.2-pter, 7q11.2, 8q11.2-qter, 9p23, 9q13-
q21, 13, 17q11.2-q24 (HLA 17q12-q21), 20q11.2-qter
8 MET loss: n.a.
gain: n.a.
9 MET loss: n.a.
gain: n.a.
10 MET loss: 19p13.2-pter
gain: n.a.
Alterations shared with the concurrent invasive cancer are printed in bold.
MET, metaplasia; LGD, low-grade dysplasia; HGD, high-grade dysplasia; HLA, high-level amplification; n.a., no aberrations.
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attributed to the lower sensitivity of CGH, as compared to
LOH analysis.30 Furthermore, the frequency of TP53 al-
terations might be somewhat lower in gastric cardia can-
cers than in esophageal (Barrett’s) adenocarcinomas.31
The determination of two regions of loss on 5q might point
to two sites for putative tumor suppressors. The 5q21
region contains the mutated in colorectal cancer (MCC)
and adenomatous polyposis coli (APC) genes, which
have been shown to be involved in Barrett-related can-
cers. The loss at 5q31-q33 might involve a-catenin (CT-
NNA1, locus at 5q31), which is part of the E-cadherin-
catenin complex. The loss at 18q12-q21 might be related
to DCC (deleted in colorectal carcinoma) and/or DPC4
(deleted in pancreatic carcinoma), genes known to be
Figure 2. Photomicrographs illustrating pairs of preneoplastic lesions (A, C, and E) and adenocarcinoma (B, D, and F) of the gastric cardia. Case 3 showed
intestinal metaplasia (A) adjacent to poorly differentiated adenocarcinoma (B). Precursor and cancer shared gain of the X chromosome, whereas in this metaplastic
tissue also loss on 18q was disclosed by CGH. Case 6 displayed high-grade dysplasia (C) and poorly differentiated adenocarcinoma (D). Many alterations (12 of
17) detected by CGH in the dysplasia were also discerned in the invasive cancer. Case 7 demonstrated HGD (E) and moderately differentiated adenocarcinoma
(F). CGH revealed a basically similar pattern of chromosomal aberrations, despite the clear differences in histomorphology of the two lesions, ie, a non-invasive
histology in HGD versus the invasive growth pattern of the adenocarcinoma.
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altered in gastrointestinal cancers. A high frequency of
loss is observed on chromosome 4, but it was not possi-
ble to assign a common region on each of the two chro-
mosome arms. This could be due to a high density of
tumor suppressor genes on this chromosome, which is in
concordance with a LOH study of chromosome 4q in
Barrett’s adenocarcinoma.32
Chromosomal Gain
The most prominent gain was found on chromosome 20,
especially 20q (80%), with a minimal region at 20q11.2-
q13.1. HLA was detected on 20q13.1. It is noteworthy
that in a recent CGH array investigation of breast carci-
nomas, CYP24, encoding vitamin D24 hydroxylase, and
located at 20q13.2, was discriminated as a putative on-
cogene.33 High-frequency gain was also noted on 8q
with a minimally gained region at 8q21.3-q23, which is
slightly proximal to the MYC (v-myc myelocytomatosis on-
cogene) locus. Expression studies have shown that, eg,
epidermal growth factor receptor, Kirsten rat sarcoma viral
oncogene homologue, or v-erb-b2 oncogene (HER2-neu)
are involved in the malignant transformation of Barrett’s
esophagus,34 which may explain the gains and amplifica-
tions at 7p12-p14, 12p11.2, and 17q12-q21. The amplifica-
tion on 7q21 is associated more with hepatocyte growth
factor (HGF) than with the more distally located MET onco-
gene, encoding for the HGF receptor. HGF serum levels
were reported to correlate significantly with the aggres-
siveness of gastric carcinomas.35 Immunohistochemistry
showed that MET was overexpressed in about half of gas-
tric cancers, whereas gene amplification was detected by
Southern blot hybridization in about 10% of them.36 The
recurrent HLA at 8p might be associated with cathepsin B,
which appears to be amplified and overexpressed in Bar-
rett-related carcinomas.37 HLA at 19q13.1-q13.2 might in-
volve cyclin E, which has recently been described as the
candidate gene of a 19q12 amplicon in adenocarcinomas
of the gastro-esophageal junction.38
The genetic spectrum of imbalances in gastric cardia
cancers, disclosed by CGH, is very similar to the distri-
bution of alterations seen in Barrett-related adenocarci-
nomas.24,39 It is also in keeping with allelotyping and in
situ hybridization studies of esophageal adenocarcino-
ma.40–42 Furthermore, the pattern of gains and losses in
the preneoplastic lesions shows a high degree of simi-
larity to the genetic changes seen in Barrett’s esophagus
39,43–46, ie, losses in cardia cancer precursor lesions are
frequently seen on 4p, 5q, 9p, and 18q, whereas gains
are repeatedly found on 7q, 8q, 17q, and 20q. This
illustrates, moreover, that adenocarcinomas at these two
locations have much in common, although a minor pro-
portion of proximal stomach cancers might be related to
H. pylori infection. However, our data strongly suggest a
shared etiology of gastro-esophageal junction adenocar-
cinomas arising either in the distal esophagus (Barrett’s
esophagus) or in the gastric cardia.
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